Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018039581) USE OF HDAC6 INHIBITORS FOR PREVENTING AND TREATING RENAL CYSTOGENESIS, RENAL CELL CARCINOMA, AND RENAL CILIOPATHIES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/039581 International Application No.: PCT/US2017/048646
Publication Date: 01.03.2018 International Filing Date: 25.08.2017
IPC:
A61K 31/505 (2006.01) ,A61K 31/506 (2006.01) ,A61P 13/12 (2006.01) ,A61P 43/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13
Drugs for disorders of the urinary system
12
of the kidneys
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
43
Drugs for specific purposes, not provided for in groups A61P1/-A61P41/108
Applicants:
THE TEXAS A&M UNIVERSITY SYSTEM [US/US]; 3369 TAMU College Station, TX 77843-3369, US
Inventors:
DERE, Ruhee; US
WALKER, Cheryl L.; US
JONASCH, Eric; US
Agent:
NOWAK, Thomas Stasiu; US
Priority Data:
62/380,31426.08.2016US
Title (EN) USE OF HDAC6 INHIBITORS FOR PREVENTING AND TREATING RENAL CYSTOGENESIS, RENAL CELL CARCINOMA, AND RENAL CILIOPATHIES
(FR) UTILISATION D’INHIBITEURS DE HDAC6 POUR LA PRÉVENTION ET LE TRAITEMENT DE LA CYSTOGENÈSE RÉNALE, D’UN CARCINOME À CELLULES RÉNALES ET DE CILIOPATHIES RÉNALES
Abstract:
(EN) The present disclosure is directed to the use of HDAC6 inhibitors for the treatment of renal diseases and disorders, including ciliopathy, Von Hippel-Lindau (VHL) disease, renal cystogenesis, renal cell carcinoma, and Tuberous Sclerosis Complex (TSC), and the like. In some embodiments, the HDAC6 inhibitor is a direct inhibitor of HDAC6. In a further embodiment, the HDAC6 signaling inhibitor is ACY-1215 or a pharmaceutically acceptable salt thereof. In some embodiments, the HDAC6 inhibitor is combined with an AURKA inhibitor.
(FR) La présente invention concerne l’utilisation d’inhibiteurs de HDAC6 pour le traitement de maladies et troubles rénaux, comprenant une ciliopathie, la maladie de Von Hippel-Lindau (VHL), la cystogenèse rénale, un carcinome à cellules rénales et le complexe de la sclérose tubéreuse (CST), et similaire. Dans certains modes de réalisation, l’inhibiteur de HDAC6 est un inhibiteur direct de HDAC6. Dans un autre mode de réalisation, l’inhibiteur de signalisation HDAC6 est ACY-1215 ou un sel pharmaceutiquement acceptable de celui-ci. Dans certains modes de réalisation, l’inhibiteur de HDAC6 est combiné avec un inhibiteur d’AURKA.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)